Impact of Native Chicory Inulin on Change and Persistence of Gut Microbiota
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Inulin, Maltodextrin.
- Who it may be relevant to
- Registry conditions: Healthy. Basic parameters: 18 years — 45 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Native Chicory Inulin Supplementation on Rates of Microbial Change Between Individuals
Overview
The main aim of this study is to investigate differences in rate, extent of change and persistence of the gut microbiota in healthy adult volunteers in response to native chicory inulin. Along with investigating the impact of native chicory on bowl habits, mood and appetite. The two main questions this study aims to answer: * To what extent do differences exist in rate of change over time between individuals in gut microbiota response (Bifidobacterium growth) to native chicory inulin supplementation. * To what extent do differences exist between individuals in persistence of the gut microbiota upon stopping supplementation. The effects of native chicory inulin on gut microbiota response will be compared to a maltodextrin placebo to sure changes in gut microbiota result directly from chicory inulin supplementation. Participants will firstly complete a one-week run-in phase to establish baseline data and will then be allocated to either native chicory inulin or maltodextrin supplementation for 6 weeks. Inulin will be delivered at 12 g/day split into 2 x 6g portions. Maltodextrin will be calorie matched at 6 g/day split into 2 x 3g portions. This will then be followed by a 6 week post-supplementation phase. Fecal and blood samples will be collected regularly throughout all phases for analysis of gut microbiota and compounds of interest. Participants will also record any changes in gastrointestinal sensation, bowel habits and mood in a diary. Changes in appetite sensation will also measured.
Detailed description
The term prebiotic was established in 1995 and has since undergone several updates in definition. As of 2017, the International Scientific Association for Probiotics and Prebiotics (ISAPP) defines prebiotics as a substrates that is selectivity utilised by the host microorganism conferring a health benefit. Of all prebiotics the most highly researched prebiotics are inulin and fructo-oligosaccharides that belong to a group of non-digestible carbohydrates referred to as inulin-type fructans. The main concept behind prebiotics is to stimulate selective changes in microbiota - namely Bifidobacterium in regards to inulin-type fructans. The ability for inulin-type fructans to stimulate changes in bifidobacteria has been demonstrated across across a wide array of studies. Yet, while in vivo studies suggest that inulin-type fructans exert a bifidogenic effect, substantial differences in changes in bifidobacteria responses are often documented between individuals. More specifically, evidence is lacking regarding differences in the rate, extent of change and persistence of the gut microbiota upon the commencement and seizing of inulin supplementation. While, increasing pre-clinical data suggests that a wide variety of bacteria found within the gut can utilise inulin-type fructans in addition to just Bifidobacterium. The aims of this research study are to explore effects that supplementation with 12 g/day inulin-type fructans has on frequent changes in gut microbiota load, composition, gastrointestinal sensation (flatulence, intestinal bloating, abdominal pain and abdominal pressure), bowel habits (stool frequency and stool consistency) and mood with maltodextrin employed as a placebo ((control) 6 g/day). This study will also examine differences in appetite sensation and blood metabolites. The study will consist of 3 phases - a one-week run-in phase; a 6-week supplementation phase and a 6-week post-supplementation phase.
Interventions
- Other Inulin
12 g/day prebiotic supplement taken daily split into 2 dosages of 6 g dissolved in water - Other Maltodextrin
6 g/day maltodextrin taken daily split into 2 dosages of 3 g dissolved in water
Primary outcome measures
- Changes in Bifidobacterium counts in stool samples [Time frame: 13 weeks]
Secondary outcome measures (12)
- Total bacteria in stool samples [Time frame: 13 weeks]
- Changes in gut bacterial composition [Time frame: 13 weeks]
- Changes in gut fermentation kinetics [Time frame: 10 days over 13 weeks]
- Changes in short-chain fatty acid production [Time frame: 10 times over 13 weeks]
- Stool frequency [Time frame: 13 week]
- Stool consistency according to Bristol Stool Form Scale [Time frame: 13 week]
- Gastrointestinal sensations (bloating) [Time frame: 13 week]
- Gastrointestinal sensations (flatulence) [Time frame: 13 week]
- Gastrointestinal sensations (abdominal pain) [Time frame: 13 week]
- Gastrointestinal sensations (abdominal pressure) [Time frame: 13 week]
- Appetite - Feeling of Fullness? [Time frame: 12 weeks]
- Appetite - Feeling of hunger? [Time frame: 12 weeks]
Eligibility criteria
Inclusion criteria
- adults aged 18-45
- BMI >18.5 - < 30 kg/m2
- Regular bowel movements (> 4 days per week)
Exclusion criteria
- Self-reported sensitivity to FODMAPs and following a low FODMAP diet ((FODMAPS stands for fermentable oligosaccharides, disaccharides, monosaccharides and polyols).
- Self-reported food allergies and sensitivities including gluten, dairy, nuts, soya and lactose etc.
- Self-reported antibiotic treatment in the past 6 months.
- Self-reported history of gastrointestinal disease and/or heart disease, cardiovascular, liver, and respiratory disorders, cancer and/or clinically relevant (pre) diabetes.
- Self-reported to having undergone major surgery of the gastrointestinal tract, with the exception of cholecystectomy and appendectomy.
- Self-reported smoking and/or self-reported drug or alcohol abuse.
- Self-reported history of psychiatric and/or mood disorders including eating disorders.
- Self-reported to be following a restrictive diet (i.e. ketogenic, intermittent fasting).
- Pregnant and lactating women.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Other
Study locations
United States · 1 center
- Purdue University — West Lafayette
Identifiers
NCT: NCT06528041 · IRB-2024-154